# Venetoclax and Acalabrutinib in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma

> **NCT03946878** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **M.D. Anderson Cancer Center** · enrollment: 32 (actual)

## Conditions studied

- Blastoid Variant Mantle Cell Lymphoma
- CCND1 Protein Overexpression
- CD20 Positive
- CD5 Positive
- FCER2 Negative
- Pleomorphic Variant Mantle Cell Lymphoma
- Recurrent Mantle Cell Lymphoma
- Refractory Mantle Cell Lymphoma
- t(11;14)(q13;q32)

## Interventions

- **DRUG:** Acalabrutinib
- **DRUG:** Venetoclax

## Key facts

- **NCT ID:** NCT03946878
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2019-08-13
- **Primary completion:** 2028-02-08
- **Final completion:** 2028-02-08
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2026-02-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03946878

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03946878, "Venetoclax and Acalabrutinib in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT03946878. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*